Akoya Biosciences Inc (NAS:AKYA)

$ 2.4335 -0.1165 (-4.57%) Market Cap: 126.39 Mil Enterprise Value: 165.50 Mil PE Ratio: 0 PB Ratio: 9.11 GF Score: 46/100

Q3 2024 Akoya Biosciences Inc Earnings Call Transcript
Nov 14, 2024

$3.13 (-2.49%)

Earnings
Q2 2024 Akoya Biosciences Inc Earnings Call Transcript
Aug 05, 2024

$2.15 (-3.15%)

Earnings
Q1 2024 Akoya Biosciences Inc Earnings Call Transcript
May 13, 2024

$4.12 (-3.40%)

Earnings
Q4 2023 Akoya Biosciences Inc Earnings Call Transcript
Mar 04, 2024

$5.98 (-0.83%)

Earnings
Akoya Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 10, 2024
Q3 2023 Akoya Biosciences Inc Earnings Call Transcript
Nov 08, 2023

$3.76 (-0.79%)

Earnings
Akoya Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 13, 2023
Akoya Biosciences Inc at Canaccord Genuity Growth Conference Transcript
Aug 09, 2023
Q2 2023 Akoya Biosciences Inc Earnings Call Transcript
Aug 07, 2023

$6.32 (-2.02%)

Earnings
Q1 2023 Akoya Biosciences Inc Earnings Call Transcript
May 08, 2023

$6.44 (-5.99%)

Earnings
Q4 2022 Akoya Biosciences Inc Earnings Call Transcript
Mar 06, 2023

$11.15 (-5.11%)

Earnings
Akoya Biosciences Inc at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Akoya Biosciences Inc Spatial Day Transcript
Dec 15, 2022
Q3 2022 Akoya Biosciences Inc Earnings Call Transcript
Nov 07, 2022

$13.01 (-5.86%)

Earnings
Akoya Biosciences Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
Q2 2022 Akoya Biosciences Inc Earnings Call Transcript
Aug 08, 2022

$15.02 (+1.76%)

Earnings
Akoya Biosciences Inc at UBS Global Life Science Conference (Virtual) Transcript
May 23, 2022
Akoya Biosciences Inc at Bank of America Healthcare Conference Transcript
May 10, 2022
Q1 2022 Akoya Biosciences Inc Earnings Call Transcript
May 05, 2022

$10.15 (-8.06%)

Earnings
Q4 2021 Akoya Biosciences Inc Earnings Call Transcript
Mar 14, 2022

$10.74 (+9.15%)

Earnings
Akoya Biosciences Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Akoya Biosciences Inc Spatial Day Transcript
Dec 15, 2021
Q3 2021 Akoya Biosciences Inc Earnings Call Transcript
Nov 08, 2021

$12.91 (-3.01%)

Earnings
Akoya Biosciences Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Q2 2021 Akoya Biosciences Inc Earnings Call Transcript
Aug 10, 2021

$17.99 (+0.50%)

Earnings
Q1 2021 Akoya Biosciences Inc Earnings Call Transcript
May 18, 2021

$19.73 (-2.18%)

Earnings

Q4 2023 Akoya Biosciences Inc Earnings Call Transcript

Mar 04, 2024 / 10:00PM GMT

Release Date Price: $5.98 (-0.83%)

Transcript 10-K8-K

Operator

Good day and thank you for standing by, and welcome to the Akoya Biosciences's fourth-quarter 2023 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.

And I would now like to hand the conference over to your first speaker today, Priyam Shah, Head of Investor Relations. Please go ahead.

Priyam Shah

Akoya Biosciences Inc - Head, Investor Relations

Thank you, operator, and thank you to everyone who's joining us today on this call. I'm Priyam Shah, Head of Investor Relations at Akoya Biosciences. On the call today, we have Brian McKelligon, Chief Executive Officer; and Johnny Ek, Chief Financial Officer.

Earlier today, Akoya released financial results for the fourth quarter ended December 31, 2023. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of Federal Securities laws, which are made pursuant to the Safe

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.